Eli Lilly announced it was to set up a new bio manufacturing plant in Ireland, in February 2012. The plant will be located at the company's campus in Kinsale, Cork.
Eli Lilly broke ground for a biopharmaceutical development and manufacturing facility at Kinsale in 2006. The facility was inaugurated in 2010 and is set to begin full scale commercial production in 2013. The latest manufacturing plant announced in 2012 will add another commercialisation and manufacturing facility to the Kinsale site.
The new project is expected to create 300 jobs during the onsite building works. It will employ 200 pharmaceutical professionals upon commencement of operations. It will thus generate 500 jobs, including high skill and low skill.
Construction is expected to begin later in 2012 and the facility will be opened in 2016. The staff recruitment will begin in 2013.
Eli Lilly's planned growth project
"IDA Ireland, the organisation responsible for bringing foreign direct investments to Ireland, has worked closely with Eli Lilly to attract investment."
The project is undertaken as part of Eli Lilly's planned growth strategy in biopharmaceutical business.
IDA Ireland, the organisation that is responsible for bringing foreign direct investments to Ireland, has worked closely with Eli Lilly to attract the company's further investment into the republic to foster employment and industrial growth.
The Action Plan for Jobs, announced by the Irish Government, included the measures it will take to create new jobs in the country in 2012.
It was principally targeted at attracting investments by multinational companies operating in high-end manufacturing and health / life sciences sectors, such as Eli Lilly.
IDA Ireland achieved a significant start up to achieving the targets of the Action Plan by encouraging Eli Lilly's expansion in the country.
New facility at Kinsale, Cork
The new biopharmaceutical commercialisation and manufacturing facility will be built over an area 240,000 square feet near the existing facility at the Kinsale site.
Eli Lilly's expansion at its existing Kinsale campus and drugs produced
Announcement of the new manufacturing plant is Eli Lilly's second big investment at Kinsale. The company announced the first investment of €300m ($400m) at the location in 2006. The total investment made by the company in the Kinsale facility reached more than €1bn by 2012.
The main focus areas for the new plant will be cancer and diabetes drugs. The drugs manufactured will not be in final dosage form.
They will be shipped to finishing plants of the company located in different parts of the world. The finishing plants will convert them to tablets, capsules or injectibles, depending on the drug's approved dosage form.
Eli Lilly's manufacturing base in Ireland
Eli Lilly's manufacturing history in Ireland dates back to 1981 when the company established its first manufacturing facility in the republic.
"The manufacturing plant is Eli Lilly's second big investment at Kinsale. The company announced the first of €300m ($400m) in 2006."
Eli Lilly is headquartered in Indianapolis, US. The Irish branch of the company is located in Dunderrow, Kinsale.
The company currently has four manufacturing sites in the country, including Kinsale, Cork City, Sligo and Dublin.
These production facilities manufacture bulk quantities of active pharmaceutical ingredients (API), biopharmaceutical products and animal vaccines.
Some of the drugs manufactured by these sites include Alimta, Evista, Strattera and Zyprexa.
The existing facility at Kinsale is involved in development as well as commercialisation of new products.
Marketing commentary for the pharmaceutical giant
The pharmaceutical sector plays a key role in the Irish industrial and economic growth as the industy is the second largest in Ireland. The republic has witnessed more than €7bn investment in pharmaceuticals in the last decade.
It has eventually grown to become the world's biggest net exporter of pharmaceuticals.
Eli Lilly has attracted and invested significantly in a skilled workforce at the existing Kinsale manufacturing facility, therefore, expanding the site will provide synergistic benefits.
0 comments:
Post a Comment